The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.
Over 19 years old
Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information
Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery disease
Patients with TIMI ≤ 2 before coronary intervention
Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)
Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration